PLIANT THERAPEUTICS INC. - COMMON STOCK

Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024

26 Aug 2024 09:10:07 By Nasdaq GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

07 Aug 2024 16:05:00 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference

06 Aug 2024 16:03:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple Measures

15 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors

13 Jun 2024 16:05:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

12 Jun 2024 16:05:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™

06 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference

21 May 2024 18:50:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis

14 May 2024 07:30:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™

07 May 2024 08:00:01 By Nasdaq GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

06 May 2024 16:05:00 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Events

01 May 2024 08:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Events

02 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference

27 Mar 2024 10:23:38 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis

12 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results

27 Feb 2024 16:03:00 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Conferences

26 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Events

07 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

04 Feb 2024 15:29:07 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

03 Jan 2024 08:00:00 By Nasdaq GlobeNewswire